218 related articles for article (PubMed ID: 31940398)
1. Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
Anchoori RK; Tan M; Tseng SH; Peng S; Soong RS; Algethami A; Foran P; Das S; Wang C; Wang TL; Liang H; Hung CF; Roden RBS
PLoS One; 2020; 15(1):e0227727. PubMed ID: 31940398
[TBL] [Abstract][Full Text] [Related]
2. Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling.
Soong RS; Anchoori RK; Roden RBS; Cho RL; Chen YC; Tseng SC; Huang YL; Liao PC; Shyu YC
BMC Cancer; 2020 May; 20(1):386. PubMed ID: 32375699
[TBL] [Abstract][Full Text] [Related]
3. Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.
Anchoori RK; George L; Tseng SH; Lam B; Polkampally S; Amiano AD; Foran P; Tsingine H; Samanapally H; Carrizo Velasquez F; Das S; Xing D; Bin Salam A; Karanam B; Hung CF; Roden RBS
PLoS One; 2021; 16(9):e0256937. PubMed ID: 34506530
[TBL] [Abstract][Full Text] [Related]
4. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.
Anchoori RK; Karanam B; Peng S; Wang JW; Jiang R; Tanno T; Orlowski RZ; Matsui W; Zhao M; Rudek MA; Hung CF; Chen X; Walters KJ; Roden RB
Cancer Cell; 2013 Dec; 24(6):791-805. PubMed ID: 24332045
[TBL] [Abstract][Full Text] [Related]
5. Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.
Lu X; Nowicka U; Sridharan V; Liu F; Randles L; Hymel D; Dyba M; Tarasov SG; Tarasova NI; Zhao XZ; Hamazaki J; Murata S; Burke TR; Walters KJ
Nat Commun; 2017 Jun; 8():15540. PubMed ID: 28598414
[TBL] [Abstract][Full Text] [Related]
6. Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.
Jiang RT; Yemelyanova A; Xing D; Anchoori RK; Hamazaki J; Murata S; Seidman JD; Wang TL; Roden RBS
J Ovarian Res; 2017 Aug; 10(1):53. PubMed ID: 28784174
[TBL] [Abstract][Full Text] [Related]
7. Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.
Dickson P; Abegg D; Vinogradova E; Takaya J; An H; Simanski S; Cravatt BF; Adibekian A; Kodadek T
Cell Chem Biol; 2020 Nov; 27(11):1371-1382.e6. PubMed ID: 32857985
[TBL] [Abstract][Full Text] [Related]
8. Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.
Anchoori RK; Anchoori V; Lam B; Tseng SH; Das S; Velasquez FC; Karanam B; Poddatoori D; Patnam R; Rudek MA; Chang YN; Roden RBS
PLoS One; 2023; 18(6):e0285221. PubMed ID: 37315065
[TBL] [Abstract][Full Text] [Related]
9. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
Song Y; Park PMC; Wu L; Ray A; Picaud S; Li D; Wimalasena VK; Du T; Filippakopoulos P; Anderson KC; Qi J; Chauhan D
Leukemia; 2019 Nov; 33(11):2685-2694. PubMed ID: 30962579
[TBL] [Abstract][Full Text] [Related]
10. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
11. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.
Song Y; Ray A; Li S; Das DS; Tai YT; Carrasco RD; Chauhan D; Anderson KC
Leukemia; 2016 Sep; 30(9):1877-86. PubMed ID: 27118409
[TBL] [Abstract][Full Text] [Related]
12. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
13. A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
Trader DJ; Simanski S; Kodadek T
J Am Chem Soc; 2015 May; 137(19):6312-9. PubMed ID: 25914958
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy.
Aliabadi F; Sohrabi B; Mostafavi E; Pazoki-Toroudi H; Webster TJ
Open Biol; 2021 Apr; 11(4):200390. PubMed ID: 33906413
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.
Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M
Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
Du T; Song Y; Ray A; Chauhan D; Anderson KC
Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294
[TBL] [Abstract][Full Text] [Related]
18. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
19. Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates.
Besche HC; Sha Z; Kukushkin NV; Peth A; Hock EM; Kim W; Gygi S; Gutierrez JA; Liao H; Dick L; Goldberg AL
EMBO J; 2014 May; 33(10):1159-76. PubMed ID: 24811749
[TBL] [Abstract][Full Text] [Related]
20. The significance of ubiquitin proteasome pathway in cancer development.
Yerlikaya A; Yöntem M
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
